180
Participants
Start Date
April 8, 2016
Primary Completion Date
August 15, 2018
Study Completion Date
November 29, 2023
Palbociclib 100mg
100mg PO daily
Palbociclib 125mg
125mg PO daily 3 weeks out of 4
Fulvestrant or Tamoxifen or Aromatase Inhibitor
given at the standard doses/schedules
Cross Cancer Institute, Edmonton
BCCA - Abbotsford Centre, Abbotsford
BCCA - Fraser Valley Cancer Centre, Surrey
BCCA - Vancouver Cancer Centre, Vancouver
The Moncton Hospital, Moncton
Dr. H. Bliss Murphy Cancer Centre, St. John's
QEII Health Sciences Centre, Halifax
Royal Victoria Regional Health Centre, Barrie
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton
Cancer Centre of Southeastern Ontario at Kingston, Kingston
Stronach Regional Health Centre at Southlake, Newmarket
Lakeridge Health Oshawa, Oshawa
Ottawa Hospital Research Institute, Ottawa
Niagara Health System, St. Catharines
University Health Network, Toronto
Windsor Regional Cancer Centre, Windsor
CHUM - Hopital Notre-Dame, Montreal
The Jewish General Hospital, Montreal
Hopital du Sacre-Coeur de Montreal, Montreal
CHA-Hopital Du St-Sacrement, Québec
Centre hospitalier universitaire de Sherbrooke, Sherbrooke
Allan Blair Cancer Centre, Regina
Collaborators (1)
Pfizer
INDUSTRY
Canadian Cancer Trials Group
NETWORK